(Q51332907)

English

Efficacy and safety of lixisenatide once daily vs. placebo in people with Type 2 diabetes insufficiently controlled on metformin (GetGoal-F1).

scientific article published on 24 October 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 April 2018

http://europepmc.org/abstract/MED/24117597

Efficacy and safety of lixisenatide once daily vs. placebo in people with Type 2 diabetes insufficiently controlled on metformin (GetGoal-F1). (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 April 2018

http://europepmc.org/abstract/MED/24117597

type 2 diabetes

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Markolf Hanefeld

7

object named as

M Hanefeld

1 reference

Europe PubMed Central

PubMed publication ID

3 April 2018

author name string

G B Bolli

1

1 reference

Europe PubMed Central

PubMed publication ID

3 April 2018

http://europepmc.org/abstract/MED/24117597

M Munteanu

2

1 reference

Europe PubMed Central

PubMed publication ID

3 April 2018

http://europepmc.org/abstract/MED/24117597

S Dotsenko

3

1 reference

Europe PubMed Central

PubMed publication ID

3 April 2018

http://europepmc.org/abstract/MED/24117597

E Niemoeller

4

1 reference

Europe PubMed Central

PubMed publication ID

3 April 2018

http://europepmc.org/abstract/MED/24117597

G Boka

5

1 reference

Europe PubMed Central

PubMed publication ID

3 April 2018

http://europepmc.org/abstract/MED/24117597

Y Wu

6

1 reference

Europe PubMed Central

PubMed publication ID

3 April 2018

http://europepmc.org/abstract/MED/24117597

publication date

24 October 2013

1 reference

Europe PubMed Central

PubMed publication ID

3 April 2018

http://europepmc.org/abstract/MED/24117597

Diabetic Medicine

1 reference

Europe PubMed Central

PubMed publication ID

3 April 2018

http://europepmc.org/abstract/MED/24117597

31

1 reference

Europe PubMed Central

PubMed publication ID

3 April 2018

http://europepmc.org/abstract/MED/24117597

2

1 reference

Europe PubMed Central

PubMed publication ID

3 April 2018

http://europepmc.org/abstract/MED/24117597

176-184

1 reference

Europe PubMed Central

PubMed publication ID

3 April 2018

http://europepmc.org/abstract/MED/24117597

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

1 reference

https://api.crossref.org/works/10.1111%2FDME.12328

21 January 2018

Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control

1 reference

https://api.crossref.org/works/10.1111%2FDME.12328

21 January 2018

The safety and tolerability of GLP-1 receptor agonists in the treatment of type 2 diabetes: a review

1 reference

https://api.crossref.org/works/10.1111%2FDME.12328

21 January 2018

Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics)--preclinical and clinical results

1 reference

https://api.crossref.org/works/10.1111%2FDME.12328

21 January 2018

Once-weekly GLP-1 agonists: How do they differ from exenatide and liraglutide?

1 reference

https://api.crossref.org/works/10.1111%2FDME.12328

21 January 2018

An overview of once-weekly glucagon-like peptide-1 receptor agonists--available efficacy and safety data and perspectives for the future.

1 reference

https://api.crossref.org/works/10.1111%2FDME.12328

21 January 2018

Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FDME.12328

21 January 2018

Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono)

1 reference

https://api.crossref.org/works/10.1111%2FDME.12328

21 January 2018

Pharmacological profile of lixisenatide: A new GLP-1 receptor agonist for the treatment of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FDME.12328

21 January 2018

Lixisenatide for type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1111%2FDME.12328

21 January 2018

Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia).

1 reference

https://api.crossref.org/works/10.1111%2FDME.12328

21 January 2018

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FDME.12328

21 January 2018

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study

1 reference

https://api.crossref.org/works/10.1111%2FDME.12328

21 January 2018

Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial

1 reference

https://api.crossref.org/works/10.1111%2FDME.12328

21 January 2018

Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study

1 reference

https://api.crossref.org/works/10.1111%2FDME.12328

21 January 2018

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

1 reference

https://api.crossref.org/works/10.1111%2FDME.12328

21 January 2018

Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials

1 reference

https://api.crossref.org/works/10.1111%2FDME.12328

21 January 2018

Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations

1 reference

https://api.crossref.org/works/10.1111%2FDME.12328

21 January 2018

Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin

1 reference

https://api.crossref.org/works/10.1111%2FDME.12328

21 January 2018

Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

1 reference

https://api.crossref.org/works/10.1111%2FDME.12328

21 January 2018

Identifiers

10.1111/DME.12328

1 reference

Europe PubMed Central

PubMed publication ID

3 April 2018

http://europepmc.org/abstract/MED/24117597

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 April 2018

http://europepmc.org/abstract/MED/24117597

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51332907&oldid=1236714967"